Cellicon Valley '23: The Future of Cell and Gene Therapies

LIVEAAPACMECNEOpioid

Add to Calendar Cellicon Valley '23: The Future of Cell and Gene Therapies 6/22/2023 11:20:00 AM 6/22/2023 3:40:00 PM America/New_York For More Details: https://upenn.cloud-cme.com/course/courseoverview?EID=83474 Description: As home to the first FDA-approved cell and gene therapies, Penn Medicine and Children’s Hospital of Philadelphia are international leaders who have helped propel Philadelphia into Cellicon Valley, with the University of Pennsylvania ranking 1st among global universities for CAR-T cell patents, according to Nature Biotechnology. CAR T represents a turning point in the history of human medicine, a genuin... Irvine Auditorium / AJI Media Livecast false MM/DD/YYYY


Thursday, June 22, 2023, 11:20 AM - 3:40 PM, Irvine Auditorium / AJI Media Livecast, Philadelphia, PA


As home to the first FDA-approved cell and gene therapies, Penn Medicine and Children’s Hospital of Philadelphia are international leaders who have helped propel Philadelphia into Cellicon Valley, with the University of Pennsylvania ranking 1st among global universities for CAR-T cell patents, according to Nature Biotechnology. CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to disease within the field of cellular therapy and transplant. The approvals of chimeric antigen receptor (CAR) T cells offers even patients with highly chemo-refractory hematologic malignancies additional treatment options. World experts in CAR T-cellular therapy, hematologic malignancies, and hematopoietic stem cell transplantation (HSCT) have been assembled to discuss the development and implementation of this therapy and weigh in on current applications, best practices, novel strategies and future developments for CAR T cells. Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care and understanding new strategies to optimize and improve CAR T cell therapies. Participants will leave with up-to-date, practical information which will have immediate clinical application, and an understanding of critical research initiatives that are rapidly driving this field forward. Research participants will leave with the technical and scientific background on the current state, and where the latest scientific advances may take the field.


Specialties - INTERNAL MEDICINE - Hematology, INTERNAL MEDICINE - Medical Oncology, PEDIATRICS - Pediatric Hematology-Oncology


Objectives

After completing this activity, participants should be able to:


  1. Identify current application of CAR T-cell therapy including: disease indication, accurate patient selection, manufacturing and treatment administration for adult and pediatric patients
  2. Describe the latest for CAR T-Cell Therapy for T Cell ALL, multiple myeloma and CLL
  3. List challenges and opportunities for equitable patient access
  4. Explain the risk of malignancies and curative therapies for hemoglobinopathies
  5. Identify the current status of globalization of cell and gene therapies
  6. Describe the latest targets and technologies for CARs
  7. Define toxicity and its management
  8. Identify mechanisms of resistance and how to overcome it
  9. List recent advances in cell therapy for solid tumors
  10. Describe chimeric antigen receptor T Cells for T Cell malignancies


In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit



AMA PRA Category 1 Credits™ (2.25 hours), AAPA (2.25 hours), NCPD Hours (ANCC) (2.25 hours), Non-Physician Attendance / Participation (2.25 hours), Opioid Education (2.25 hours)